BioMedTracker is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Informa
Menu

Report Library

All Reports
Datamonitor Healthcare Infectious Diseases Disease Analysis: Dengue Vaccines

November 13, 2020

Dengue virus is a member of the Flaviviridae family, which are also known for causing other diseases including yellow fever, West Nile virus, and tick-borne encephalitis. There are four serologically distinct dengue viruses (DENV-1, DENV-2, DENV-3, and DENV-4), meaning that recovery from infection provides immunity against a specific serotype, but there is little to no cross-immunity towards other serotypes. As a result, a person can be infected multiple times in their lifetime, with subsequent infections being more likely to be severe due to a phenomenon called antibody-dependent enhancement of disease.

Approximately 400 million people are infected with dengue annually, with 100 million displaying flu-like symptoms, and 22,000 dying from severe cases of dengue. The majority of dengue infections are mild, with patients recovering within a week; however, roughly 5% of cases manifest into a more severe version of the disease that has a rapid onset, leads to hospitalization, and is potentially life-threatening. Severe dengue is a leading cause of serious illness and death in children and adults in some Asian and Latin American countries, where the disease is endemic.

This Datamonitor Healthcare report contains a Disease Analysis module.

Indications Covered: Dengue Fever - Vaccines and Treatments
Back to the top Back to the top